慢性肾脏疾病和肌肉减少症共存与心血管疾病和死亡率的关系

IF 3.4 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Lijun Jiang, Liangliang Xu, Wen Sun, Keyu Bian, Yuan Wang
{"title":"慢性肾脏疾病和肌肉减少症共存与心血管疾病和死亡率的关系","authors":"Lijun Jiang,&nbsp;Liangliang Xu,&nbsp;Wen Sun,&nbsp;Keyu Bian,&nbsp;Yuan Wang","doi":"10.1007/s40520-025-03003-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular and mortality outcomes. However, the combined impact of CKD and sarcopenia remains poorly understood. To evaluate the combined effects of CKD and sarcopenia on cardiovascular disease (CVD) and mortality risks in a large population-based cohort.</p><h3>Methods</h3><p>We analyzed data from 477,380 participants in the UK Biobank, categorized into four groups based on the presence or absence of CKD and sarcopenia: Non-CKD Non-Sarcopenia, Non-CKD Sarcopenia, CKD Non-Sarcopenia, and CKD Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CVD and mortality outcomes. Kaplan-Meier survival analyses compared event-free survival across the groups.</p><h3>Results</h3><p>Participants with both CKD and sarcopenia exhibited the highest risks across all outcomes compared to those without either condition. For stroke, the adjusted HR was 2.17 (95% CI: 1.65–2.86), significantly higher than CKD alone (HR: 1.69, 95% CI: 1.47–1.94) or sarcopenia alone (HR: 1.28, 95% CI: 1.03–1.59). Similar trends were observed for coronary artery disease (CAD) and heart failure (HF), with HRs of 1.53 (95% CI: 1.38–1.69) and 2.22 (95% CI: 1.99–2.47), respectively, in the CKD-sarcopenia group. The coexistence of CKD and sarcopenia was also associated with significantly elevated all-cause mortality (HR: 2.59, 95% CI: 2.17–3.09) and cardiovascular-specific mortality (HR: 4.08, 95% CI: 2.95–5.66).</p><h3>Conclusion</h3><p>The coexistence of CKD and sarcopenia significantly amplifies the risks of CVD and mortality, highlighting the need for integrated management strategies to address this high-risk population. Early detection and tailored interventions targeting these dual risk factors may mitigate their compounded burden and improve clinical outcomes.</p></div>","PeriodicalId":7720,"journal":{"name":"Aging Clinical and Experimental Research","volume":"37 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40520-025-03003-w.pdf","citationCount":"0","resultStr":"{\"title\":\"Association between the coexistence of chronic kidney disease and sarcopenia with cardiovascular disease and mortality\",\"authors\":\"Lijun Jiang,&nbsp;Liangliang Xu,&nbsp;Wen Sun,&nbsp;Keyu Bian,&nbsp;Yuan Wang\",\"doi\":\"10.1007/s40520-025-03003-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular and mortality outcomes. However, the combined impact of CKD and sarcopenia remains poorly understood. To evaluate the combined effects of CKD and sarcopenia on cardiovascular disease (CVD) and mortality risks in a large population-based cohort.</p><h3>Methods</h3><p>We analyzed data from 477,380 participants in the UK Biobank, categorized into four groups based on the presence or absence of CKD and sarcopenia: Non-CKD Non-Sarcopenia, Non-CKD Sarcopenia, CKD Non-Sarcopenia, and CKD Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CVD and mortality outcomes. Kaplan-Meier survival analyses compared event-free survival across the groups.</p><h3>Results</h3><p>Participants with both CKD and sarcopenia exhibited the highest risks across all outcomes compared to those without either condition. For stroke, the adjusted HR was 2.17 (95% CI: 1.65–2.86), significantly higher than CKD alone (HR: 1.69, 95% CI: 1.47–1.94) or sarcopenia alone (HR: 1.28, 95% CI: 1.03–1.59). Similar trends were observed for coronary artery disease (CAD) and heart failure (HF), with HRs of 1.53 (95% CI: 1.38–1.69) and 2.22 (95% CI: 1.99–2.47), respectively, in the CKD-sarcopenia group. The coexistence of CKD and sarcopenia was also associated with significantly elevated all-cause mortality (HR: 2.59, 95% CI: 2.17–3.09) and cardiovascular-specific mortality (HR: 4.08, 95% CI: 2.95–5.66).</p><h3>Conclusion</h3><p>The coexistence of CKD and sarcopenia significantly amplifies the risks of CVD and mortality, highlighting the need for integrated management strategies to address this high-risk population. Early detection and tailored interventions targeting these dual risk factors may mitigate their compounded burden and improve clinical outcomes.</p></div>\",\"PeriodicalId\":7720,\"journal\":{\"name\":\"Aging Clinical and Experimental Research\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s40520-025-03003-w.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aging Clinical and Experimental Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40520-025-03003-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Clinical and Experimental Research","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40520-025-03003-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:慢性肾脏疾病(CKD)和肌肉减少症与不良的心血管和死亡率结果独立相关。然而,CKD和肌肉减少症的联合影响仍然知之甚少。评估CKD和肌肉减少症对心血管疾病(CVD)和死亡率风险的综合影响。方法:我们分析了来自英国生物银行(UK Biobank)的477380名参与者的数据,根据是否存在CKD和肌肉减少症将其分为四组:非CKD非肌肉减少症、非CKD肌肉减少症、CKD非肌肉减少症和CKD肌肉减少症。Cox比例风险模型估计心血管疾病和死亡结果的风险比(hr), 95%置信区间(ci)。Kaplan-Meier生存分析比较了各组的无事件生存率。结果与没有CKD和肌肉减少症的参与者相比,CKD和肌肉减少症的参与者在所有结果中表现出最高的风险。对于中风,调整后的风险比为2.17 (95% CI: 1.65-2.86),显著高于CKD单独(风险比:1.69,95% CI: 1.47-1.94)或肌肉减少症单独(风险比:1.28,95% CI: 1.03-1.59)。冠心病(CAD)和心力衰竭(HF)也有类似的趋势,ckd -肌肉减少症组的hr分别为1.53 (95% CI: 1.38-1.69)和2.22 (95% CI: 1.99-2.47)。CKD和肌肉减少症的共存也与显著升高的全因死亡率(HR: 2.59, 95% CI: 2.17-3.09)和心血管特异性死亡率(HR: 4.08, 95% CI: 2.95-5.66)相关。结论CKD和肌肉减少症的共存显著增加了CVD和死亡率的风险,强调了针对这一高危人群的综合管理策略的必要性。针对这些双重危险因素的早期发现和量身定制的干预措施可能减轻其复合负担并改善临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between the coexistence of chronic kidney disease and sarcopenia with cardiovascular disease and mortality

Background

Chronic kidney disease (CKD) and sarcopenia are independently associated with adverse cardiovascular and mortality outcomes. However, the combined impact of CKD and sarcopenia remains poorly understood. To evaluate the combined effects of CKD and sarcopenia on cardiovascular disease (CVD) and mortality risks in a large population-based cohort.

Methods

We analyzed data from 477,380 participants in the UK Biobank, categorized into four groups based on the presence or absence of CKD and sarcopenia: Non-CKD Non-Sarcopenia, Non-CKD Sarcopenia, CKD Non-Sarcopenia, and CKD Sarcopenia. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for CVD and mortality outcomes. Kaplan-Meier survival analyses compared event-free survival across the groups.

Results

Participants with both CKD and sarcopenia exhibited the highest risks across all outcomes compared to those without either condition. For stroke, the adjusted HR was 2.17 (95% CI: 1.65–2.86), significantly higher than CKD alone (HR: 1.69, 95% CI: 1.47–1.94) or sarcopenia alone (HR: 1.28, 95% CI: 1.03–1.59). Similar trends were observed for coronary artery disease (CAD) and heart failure (HF), with HRs of 1.53 (95% CI: 1.38–1.69) and 2.22 (95% CI: 1.99–2.47), respectively, in the CKD-sarcopenia group. The coexistence of CKD and sarcopenia was also associated with significantly elevated all-cause mortality (HR: 2.59, 95% CI: 2.17–3.09) and cardiovascular-specific mortality (HR: 4.08, 95% CI: 2.95–5.66).

Conclusion

The coexistence of CKD and sarcopenia significantly amplifies the risks of CVD and mortality, highlighting the need for integrated management strategies to address this high-risk population. Early detection and tailored interventions targeting these dual risk factors may mitigate their compounded burden and improve clinical outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.90
自引率
5.00%
发文量
283
审稿时长
1 months
期刊介绍: Aging clinical and experimental research offers a multidisciplinary forum on the progressing field of gerontology and geriatrics. The areas covered by the journal include: biogerontology, neurosciences, epidemiology, clinical gerontology and geriatric assessment, social, economical and behavioral gerontology. “Aging clinical and experimental research” appears bimonthly and publishes review articles, original papers and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信